Enhancement of host defense mechanisms against gram positive pyogenic coccal infections with levo tetramisole (levamisole) in neonatal rats

G. W. Fisher; V. T. Oi; J. L. Kelley; John Podgore; J. W. Bass; F. S. Wagner; B. L. Gordon IInd

Enhancement of host defense mechanisms against gram positive pyogenic coccal infections with levo tetramisole (levamisole) in neonatal rats

G. W. Fisher, V. T. Oi, J. L. Kelley, John Podgore, J. W. Bass, F. S. Wagner, B. L. Gordon IInd

Research output: Contribution to journal › Article › peer-review

Abstract

Levamisole (Lev), an immunologic stimulant, was studied in newborn Wistar rats to evaluate its effectiveness in modifying infections induced by challenge with bacterial pathogens. Survival of rats pretreated with Lev, then challenged with staphylococci was 41/45, whilst it was only 3/59 in those rats pretreated with a saline placebo prior to challenge with living staphylococci (P = < .001). Survival of newborn rats pretreated with Lev prior to challenge with living streptococci was 11/12 compared with 2/13 in neonatal rats which received saline placebo prior to challenge with living streptococci (P = < .005). Lev did not kill either staphylococci or streptococci in vitro. Treatment of neonatal rats prior to staphylococcal or streptococcal challenge with Lev appeared to stimulate maturation of lymphoid tissue and thus protect the rats from bacterial challenge, in this neonatal model.

Original language	English
Pages (from-to)	193-198
Number of pages	6
Journal	Annals of Allergy
Volume	33
Issue number	4
State	Published - 1 Dec 1974

Cite this

@article{268a13fb0c7143d0b4996e556e91357e,

title = "Enhancement of host defense mechanisms against gram positive pyogenic coccal infections with levo tetramisole (levamisole) in neonatal rats",

abstract = "Levamisole (Lev), an immunologic stimulant, was studied in newborn Wistar rats to evaluate its effectiveness in modifying infections induced by challenge with bacterial pathogens. Survival of rats pretreated with Lev, then challenged with staphylococci was 41/45, whilst it was only 3/59 in those rats pretreated with a saline placebo prior to challenge with living staphylococci (P = < .001). Survival of newborn rats pretreated with Lev prior to challenge with living streptococci was 11/12 compared with 2/13 in neonatal rats which received saline placebo prior to challenge with living streptococci (P = < .005). Lev did not kill either staphylococci or streptococci in vitro. Treatment of neonatal rats prior to staphylococcal or streptococcal challenge with Lev appeared to stimulate maturation of lymphoid tissue and thus protect the rats from bacterial challenge, in this neonatal model.",

author = "Fisher, {G. W.} and Oi, {V. T.} and Kelley, {J. L.} and John Podgore and Bass, {J. W.} and Wagner, {F. S.} and {Gordon IInd}, {B. L.}",

year = "1974",

month = dec,

day = "1",

language = "English",

volume = "33",

pages = "193--198",

journal = "Annals of Allergy",

issn = "0003-4738",

publisher = "American College of Allergy, Asthma and Immunology",

number = "4",

}

TY - JOUR

T1 - Enhancement of host defense mechanisms against gram positive pyogenic coccal infections with levo tetramisole (levamisole) in neonatal rats

AU - Fisher, G. W.

AU - Oi, V. T.

AU - Kelley, J. L.

AU - Podgore, John

AU - Bass, J. W.

AU - Wagner, F. S.

AU - Gordon IInd, B. L.

PY - 1974/12/1

Y1 - 1974/12/1

N2 - Levamisole (Lev), an immunologic stimulant, was studied in newborn Wistar rats to evaluate its effectiveness in modifying infections induced by challenge with bacterial pathogens. Survival of rats pretreated with Lev, then challenged with staphylococci was 41/45, whilst it was only 3/59 in those rats pretreated with a saline placebo prior to challenge with living staphylococci (P = < .001). Survival of newborn rats pretreated with Lev prior to challenge with living streptococci was 11/12 compared with 2/13 in neonatal rats which received saline placebo prior to challenge with living streptococci (P = < .005). Lev did not kill either staphylococci or streptococci in vitro. Treatment of neonatal rats prior to staphylococcal or streptococcal challenge with Lev appeared to stimulate maturation of lymphoid tissue and thus protect the rats from bacterial challenge, in this neonatal model.

AB - Levamisole (Lev), an immunologic stimulant, was studied in newborn Wistar rats to evaluate its effectiveness in modifying infections induced by challenge with bacterial pathogens. Survival of rats pretreated with Lev, then challenged with staphylococci was 41/45, whilst it was only 3/59 in those rats pretreated with a saline placebo prior to challenge with living staphylococci (P = < .001). Survival of newborn rats pretreated with Lev prior to challenge with living streptococci was 11/12 compared with 2/13 in neonatal rats which received saline placebo prior to challenge with living streptococci (P = < .005). Lev did not kill either staphylococci or streptococci in vitro. Treatment of neonatal rats prior to staphylococcal or streptococcal challenge with Lev appeared to stimulate maturation of lymphoid tissue and thus protect the rats from bacterial challenge, in this neonatal model.

UR - http://www.scopus.com/inward/record.url?scp=0016173860&partnerID=8YFLogxK

M3 - Article

C2 - 4413243

AN - SCOPUS:0016173860

SN - 0003-4738

VL - 33

SP - 193

EP - 198

JO - Annals of Allergy

JF - Annals of Allergy

IS - 4

ER -

Enhancement of host defense mechanisms against gram positive pyogenic coccal infections with levo tetramisole (levamisole) in neonatal rats

Abstract

Other files and links

Fingerprint

Cite this